Haemonetics Corporation (NYSE:HAE – Get Free Report) shares hit a new 52-week high on Tuesday . Finally, Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Finally, Fort Washington Investment Advisors Inc. OH raised its position in shares of Haemonetics by 17.3% during the first quarter.